Singapore Clinical Trial: A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3841136 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3841136 in Healthy Participants.

Singapore, Oct. 24 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 Open-Label Study to Determine the Effect of Injection Site on the Relative Bioavailability of a Single Subcutaneous Dose of LY3841136 and to Evaluate the Pharmacokinetics of a Single Intravenous Dose of LY3841136 in Healthy Participants.'. The following are the other relevant details related to the trial:

Therapeutic Area: Clinical Pharmacology

Trial Centre(s): Lilly Centre for Pharmacology

Trial Status: NA

Principal Investigator(s): Dr Noel Mathew Varghese

Published by HT Digital Content Services with permission from Health Daily Digest....